Skip to main content
OpenTrials

Clinical trial condition

Infection, Human Immunodeficiency Virus

Explore clinical trials studying Infection, Human Immunodeficiency Virus. Study availability and eligibility vary by location and protocol.

107 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Infection, Human Immunodeficiency Virus trial results

Completed

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

NCT01384734

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Coral Gables, Florida, United States
View all 54 locations
View Trial Details
Completed

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany

NCT02076386

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Mannheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Stuttgart, Baden-Wurttemberg, Germany
  • GSK Investigational Site Tübingen, Baden-Wurttemberg, Germany
View all 38 locations
View Trial Details
Completed

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

NCT00951015

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bakersfield, California, United States
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site San Francisco, California, United States
View all 35 locations
View Trial Details
Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Aurora, Colorado, United States
View all 66 locations
View Trial Details
Completed

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site San Francisco, California, United States
  • GSK Investigational Site Washington D.C., District of Columbia, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
View Trial Details
Completed

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

NCT00920426

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • GSK Investigational Site Fort Lauderdale, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
  • GSK Investigational Site Vero Beach, Florida, United States
  • GSK Investigational Site Charlotte, North Carolina, United States
View Trial Details

Related conditions